Abstract: This invention relates to polynucleotides comprising UBE3A open reading frame (ORF) sequences, vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of a UBE3A gene or aberrant activity of a UBE3A gene product in the subject, such as Angelman Syndrome.

Abstract: A method begins with the step of preparing a drag-reducing additive by mixing a dispersion polymer with a surfactant and a solvent. The method continues with the step of forming a drag-reducing composition by combining the drag-reducing additive with an aqueous treatment fluid. The method further involves the step of injecting the drag-reducing composition into a subterranean formation, a pipeline or a gathering line.

Abstract: An oxidative breaker system for use in reducing the viscosity of a polysaccharide-based or derivatized polysaccharide-based suspension includes a silicone carrier fluid, an oxidizer, and a suspension aid. The suspension aid is preferably fumed silica. The oxidizer may be selected from the group consisting of alkali metal peroxide, transition metal peroxide, persulfate compound, bromide compound, and bromate compound. In highly preferred embodiments, the oxidizer is magnesium peroxide or calcium peroxide. Alternative carrier fluids and suspension agents are also included in the art. Also disclosed is a method for breaking a polysaccharide-based suspension with the inventive oxidative breaker system.

Abstract: The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.

Abstract: A method begins with the step of preparing a drag-reducing additive by mixing a dispersion polymer with a surfactant and a solvent. The method continues with the step of forming a drag-reducing composition by combining the drag-reducing additive with an aqueous treatment fluid. The method further involves the step of injecting the drag-reducing composition into a subterranean formation, a pipeline or a gathering line.

Abstract: A method of preparing a drag-reducing composition that includes a dispersion polymer includes steps for preparing the dispersion polymer, steps for incorporating the dispersion polymer into a drag-reducing composition, and steps for using the drag-reducing composition. The step of preparing a dispersion polymer includes preparing an aqueous mixture by adding a water-soluble salt and at least one polymeric dispersant to water and polymerizing one or more water-soluble monomers in the aqueous mixture. Once the dispersion polymer has been combined with the drag-reducing additive, the combination is injected into a subterranean formation, a pipeline or a gathering line.

Abstract: A method of preparing a drag-reducing composition that includes a dispersion polymer includes steps for preparing the dispersion polymer, steps for incorporating the dispersion polymer into a drag-reducing composition, and steps for using the drag-reducing composition. The step of preparing a dispersion polymer includes preparing an aqueous mixture by adding a water-soluble salt and at least one polymeric dispersant to water and polymerizing one or more water-soluble monomers in the aqueous mixture. Once the dispersion polymer has been combined with the drag-reducing additive, the combination is injected into a subterranean formation, a pipeline or a gathering line.

Abstract: The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.

Abstract: An oxidative breaker system for use in reducing the viscosity of a polysaccharide-based or derivatized polysaccharide-based suspension includes a silicone carrier fluid, an oxidizer, and a suspension aid. The suspension aid is preferably fumed silica. The oxidizer may be selected from the group consisting of alkali metal peroxide, transition metal peroxide, persulfate compound, bromide compound, and bromate compound. In highly preferred embodiments, the oxidizer is magnesium peroxide or calcium peroxide. Alternative carrier fluids and suspension agents are also included in the art. Also disclosed is a method for breaking a polysaccharide-based suspension with the inventive oxidative breaker system.

Abstract: The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.

Abstract: A method of preparing and using a drag-reducing composition in a well treatment operation includes the step of preparing the drag-reducing composition by mixing a polymer emulsion that includes a first surfactant and a first solvent, with a second surfactant and a second solvent. The method continues with the step of combining the drag-reducing composition with an aqueous treatment fluid. The method further includes the step of injecting the drag-reducing composition and aqueous treatment fluid into a subterranean formation, a pipeline or a gathering line.

Abstract: A method of preparing and using a drag-reducing composition in a well treatment operation includes the step of preparing the drag-reducing composition by mixing a polymer emulsion that includes a first surfactant and a first solvent, with a second surfactant and a second solvent. The method continues with the step of combining the drag-reducing composition with an aqueous treatment fluid. The method further includes the step of injecting the drag-reducing composition and aqueous treatment fluid into a subterranean formation, a pipeline or a gathering line.

Abstract: A drag-reducing additive includes 40-85% by weight of a polymer emulsion that includes a polymer, a first surfactant, and a first solvent; 10-35% by weight of a second surfactant with an HLB greater than 8; and 5-30% by weight of a second solvent. In a preferred embodiment, the second solvent includes a terpene. In another preferred embodiment, the polymer is a copolymer that includes acrylamide and acrylic acid.

Abstract: An oxidative breaker system for use in reducing the viscosity of a guar-based suspension includes a silicone oil carrier fluid, an oxidizer and a suspension aid. The suspension aid is preferably fumed silica. The oxidizer may be selected from the group consisting of alkali metal peroxide, transition metal peroxide, persulfate, bromide and bromate. In highly preferred embodiments, the oxidizer is magnesium peroxide or calcium peroxide. Also disclosed is a method for breaking a guar-based suspension with the inventive oxidative breaker system.

Abstract: An oxidative breaker system for use in reducing the viscosity of a polysaccharide-based or derivatized polysaccharide-based suspension includes a silicone carrier fluid, an oxidizer, and a suspension aid. The suspension aid is preferably fumed silica. The oxidizer may be selected from the group consisting of alkali metal peroxide, transition metal peroxide, persulfate compound, bromide compound, and bromate compound. In highly preferred embodiments, the oxidizer is magnesium peroxide or calcium peroxide. Alternative carrier fluids and suspension agents are also included in the art. Also disclosed is a method for breaking a polysaccharide-based suspension with the inventive oxidative breaker system.

Abstract: The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.

Abstract: A method of preparing and using a drag-reducing composition in a well treatment operation includes the step of preparing the drag-reducing composition by mixing a polymer emulsion that includes a first surfactant and a first solvent, with a second surfactant and a second solvent. The method continues with the step of combining the drag-reducing composition with an aqueous treatment fluid. The method further includes the step of injecting the drag-reducing composition and aqueous treatment fluid into a subterranean formation, a pipeline or a gathering line.